Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Jordan Pilkington's research focuses on dermatological conditions, particularly cutaneous T-cell lymphoma (CTCL) and Sézary syndrome. Pilkington has investigated clinical variants of CTCL in kidney transplant recipients and analyzed genes associated with mycosis fungoides, identifying genes common across stages and those linked to advanced disease. Further work has explored the use of mogamulizumab in combination therapy to improve outcomes for relapsed and refractory Sézary syndrome. Additionally, Pilkington has contributed to the medical literature by highlighting cases where benign-appearing cysts may obscure more serious underlying conditions, emphasizing the importance of differential diagnosis. Pilkington's work involves collaborations with researchers at the University of Arkansas for Medical Sciences, including Sara C. Shalin, Henry Ν. C. Wong, and Delice Kayishunge.
Metrics
- h-index: 1
- Publications: 4
- Citations: 3
Selected Publications
-
Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome (2025)
-
Not a Cyst: When a Cyst Obscures a More Nefarious Process (2025)
-
Cutaneous T-Cell Lymphoma (CTCL) Arising Post Kidney Transplant: A Review of Clinical Variants in the Literature (2023)
Collaboration Network
Top Collaborators
- Cutaneous T-Cell Lymphoma (CTCL) Arising Post Kidney Transplant: A Review of Clinical Variants in the Literature
- Not a Cyst: When a Cyst Obscures a More Nefarious Process
- Cutaneous T-Cell Lymphoma (CTCL) Arising Post Kidney Transplant: A Review of Clinical Variants in the Literature
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
- Not a Cyst: When a Cyst Obscures a More Nefarious Process
- Not a Cyst: When a Cyst Obscures a More Nefarious Process
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
Similar Researchers
Based on overlapping research topics